Chromocell Therapeutics Corp financial data

Symbol
CHRO on NYSE
Location
685 Us Highway One, North Brunswick, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.77M shares
Common Stock, Shares, Outstanding 5.82M shares
Common Stock, Value, Issued 584 USD
Weighted Average Number of Shares Outstanding, Basic 5.77M shares +476%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13K USD -74.1%
General and Administrative Expense 1.21M USD +125%
Operating Income (Loss) -1.76M USD -127%
Nonoperating Income (Expense) -7.53K USD +95.7%
Net Income (Loss) Attributable to Parent -1.77M USD -85.8%
Earnings Per Share, Basic -0.31 USD/shares +67.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.8M USD
Assets, Current 2.6M USD
Assets 2.6M USD
Accrued Liabilities, Current 363K USD
Liabilities, Current 2.79M USD
Liabilities 2.79M USD
Retained Earnings (Accumulated Deficit) -17.9M USD
Stockholders' Equity Attributable to Parent -183K USD +96.3%
Liabilities and Equity 2.6M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.99M USD -1049%
Net Cash Provided by (Used in) Financing Activities 5.67M USD +3295%
Common Stock, Shares Authorized 200M shares
Common Stock, Shares, Issued 5.82M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.41M USD +2837%
Additional Paid in Capital 17.7M USD